Brown LG - Search Results

1

Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.

Lam HM, McMullin R, Nguyen HM, Coleman I, Gormley M, Gulati R, Brown LG, Holt SK, Li W, Ricci DS, Verstraeten K, Thomas S, Mostaghel EA, Nelson PS, Vessella RL, Corey E. Lam HM, et al. Among authors: brown lg. Clin Cancer Res. 2017 May 1;23(9):2301-2312. doi: 10.1158/1078-0432.CCR-16-2054. Epub 2016 Dec 19. Clin Cancer Res. 2017. PMID: 27993966 Free PMC article.

2

A very sensitive coupled luminescent assay for cytotoxicity and complement-mediated lysis.

Corey MJ, Kinders RJ, Brown LG, Vessella RL. Corey MJ, et al. Among authors: brown lg. J Immunol Methods. 1997 Aug 22;207(1):43-51. doi: 10.1016/s0022-1759(97)00098-7. J Immunol Methods. 1997. PMID: 9328585

3

LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen.

Corey E, Brown LG, Corey MJ, Buhler KR, Vessella RL. Corey E, et al. Among authors: brown lg. Prostate. 1998 May;35(2):135-43. doi: 10.1002/(sici)1097-0045(19980501)35:2<135::aid-pros7>3.0.co;2-i. Prostate. 1998. PMID: 9568677

4

Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo.

Melchior SW, Brown LG, Figg WD, Quinn JE, Santucci RA, Brunner J, Thüroff JW, Lange PH, Vessella RL. Melchior SW, et al. Among authors: brown lg. Int J Oncol. 1999 Mar;14(3):501-8. doi: 10.3892/ijo.14.3.501. Int J Oncol. 1999. PMID: 10024683

5

Identification of the target of monoclonal antibody A6H as dipeptidyl peptidase IV/CD26 by LC MS\MS.

Hass GM, Meyer JL, Newitt RA, Labuda T, Brown L, Aebersold R, Vessella RL. Hass GM, et al. Hybridoma. 2001 Aug;20(4):231-6. doi: 10.1089/027245701753179802. Hybridoma. 2001. PMID: 11604108

6

Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol.

Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL. Corey E, et al. Among authors: brown lg. Clin Cancer Res. 2002 Apr;8(4):1003-7. Clin Cancer Res. 2002. PMID: 11948106

7

Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.

Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Corey E, et al. Among authors: brown lg, brown jm. Prostate. 2002 Jun 1;52(1):20-33. doi: 10.1002/pros.10091. Prostate. 2002. PMID: 11992617

8

A novel monoclonal antibody 107-1A4 with high prostate specificity: generation, characterization of antigen expression, and targeting of human prostate cancer xenografts.

Brown LG, Wegner SK, Wang H, Buhler KR, Arfman EW, Lange PH, Vessella RL. Brown LG, et al. Prostate Cancer Prostatic Dis. 1998 Jun;1(4):208-215. doi: 10.1038/sj.pcan.4500233. Prostate Cancer Prostatic Dis. 1998. PMID: 12496897

9

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.

Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL. Corey E, et al. Among authors: brown lg. Clin Cancer Res. 2003 Jan;9(1):295-306. Clin Cancer Res. 2003. PMID: 12538482

10

Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function.

Brubaker KD, Vessella RL, Brown LG, Corey E. Brubaker KD, et al. Among authors: brown lg. Prostate. 2003 Jun 15;56(1):13-22. doi: 10.1002/pros.10233. Prostate. 2003. PMID: 12746842

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

210 results

Search Page

Filters